June 28, 2017 / 12:54 PM / a month ago

BRIEF-FDA grants priority review of Xarelto SNDA to reduce risk of recurrent VTE

1 Min Read

June 28 (Reuters) - Janssen:

* U.S. FDA grants priority review of Xarelto® (rivaroxaban) SNDA for a 10 mg dose to reduce the risk of recurrent venous thromboembolism (VTE)

* Janssen - ‍U.S. Food and Drug Administration accepted for priority review a supplemental new drug application (SNDA) for Xarelto (rivaroxaban)​

* Janssen - ‍SNDA is to include 10 mg once-daily dose for reducing risk of VTE after atleast 6 months of standard anticoagulant therapy​‍​​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below